Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission

Impaired cardiac microvascular function contributes to diabetic cardiovascular complications although effective therapy remains elusive. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor recently approved for treatment of type 2 diabetes, promotes glycosuria excretion and offers card...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Hao, Wang, Shuyi, Zhu, Pingjun, Hu, Shunying, Chen, Yundai, Ren, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756062/
https://www.ncbi.nlm.nih.gov/pubmed/29306791
http://dx.doi.org/10.1016/j.redox.2017.12.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756062/
https://www.ncbi.nlm.nih.gov/pubmed/29306791
http://dx.doi.org/10.1016/j.redox.2017.12.019

Ejemplares similares